Literature DB >> 25367502

Hypocretin receptor 2 antagonism dose-dependently reduces escalated heroin self-administration in rats.

Brooke E Schmeichel1, Estelle Barbier2, Kaushik K Misra1, Candice Contet1, Joel E Schlosburg1, Dimitri Grigoriadis3, John P Williams3, Camilla Karlsson2, Caleb Pitcairn2, Markus Heilig2, George F Koob1, Leandro F Vendruscolo1.   

Abstract

The hypocretin/orexin (HCRT) system has been associated with both positive and negative drug reinforcement, implicating HCRT receptor 1 (HCRT-R1) signaling in drug-related behaviors for all major drug classes, including opioids. However, to date there are limited studies investigating the role of HCRT receptor 2 (HCRT-R2) signaling in compulsive-like drug seeking. Escalation of drug intake with extended access has been suggested to model the transition from controlled drug use to compulsive-like drug seeking/taking. The current study examined the effects of a HCRT-R2 antagonist, NBI-80713, on heroin self-administration in rats allowed short- (1 h; ShA) or long- (12 h; LgA) access to intravenous heroin self-administration. Results indicate that systemically administered NBI-80713 dose-dependently decreased heroin self-administration in LgA, but not in ShA, animals. Quantitative PCR analyses showed an increase in Hcrtr2 mRNA levels in the central amygdala, a stress-related brain region, of LgA rats. These observations suggest a functional role for HCRT-R2 signaling in compulsive-like heroin self-administration associated with extended access and indicate HCRT-R2 antagonism as a potential pharmacological target for the treatment of heroin dependence.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25367502      PMCID: PMC4367454          DOI: 10.1038/npp.2014.293

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  37 in total

1.  Persistent increase in the motivation to take heroin in rats with a history of drug escalation.

Authors:  S H Ahmed; J R Walker; G F Koob
Journal:  Neuropsychopharmacology       Date:  2000-04       Impact factor: 7.853

2.  Neurons containing hypocretin (orexin) project to multiple neuronal systems.

Authors:  C Peyron; D K Tighe; A N van den Pol; L de Lecea; H C Heller; J G Sutcliffe; T S Kilduff
Journal:  J Neurosci       Date:  1998-12-01       Impact factor: 6.167

3.  Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior.

Authors:  T Sakurai; A Amemiya; M Ishii; I Matsuzaki; R M Chemelli; H Tanaka; S C Williams; J A Richarson; G P Kozlowski; S Wilson; J R Arch; R E Buckingham; A C Haynes; S A Carr; R S Annan; D E McNulty; W S Liu; J A Terrett; N A Elshourbagy; D J Bergsma; M Yanagisawa
Journal:  Cell       Date:  1998-03-06       Impact factor: 41.582

4.  The neuronal organization of the supracapsular part of the stria terminalis in the rat: the dorsal component of the extended amygdala.

Authors:  G F Alheid; C A Beltramino; J S De Olmos; M S Forbes; D J Swanson; L Heimer
Journal:  Neuroscience       Date:  1998-06       Impact factor: 3.590

Review 5.  Addiction as a stress surfeit disorder.

Authors:  George F Koob; Cara L Buck; Ami Cohen; Scott Edwards; Paula E Park; Joel E Schlosburg; Brooke Schmeichel; Leandro F Vendruscolo; Carrie L Wade; Timothy W Whitfield; Olivier George
Journal:  Neuropharmacology       Date:  2013-06-06       Impact factor: 5.250

6.  The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity.

Authors:  L de Lecea; T S Kilduff; C Peyron; X Gao; P E Foye; P E Danielson; C Fukuhara; E L Battenberg; V T Gautvik; F S Bartlett; W N Frankel; A N van den Pol; F E Bloom; K M Gautvik; J G Sutcliffe
Journal:  Proc Natl Acad Sci U S A       Date:  1998-01-06       Impact factor: 11.205

7.  Chronic morphine sensitizes the brain norepinephrine system to corticotropin-releasing factor and stress.

Authors:  Guang-Ping Xu; Elisabeth Van Bockstaele; Beverly Reyes; Thelma Bethea; Rita J Valentino
Journal:  J Neurosci       Date:  2004-09-22       Impact factor: 6.167

8.  Clonidine and naltrexone in the outpatient treatment of heroin withdrawal.

Authors:  H D Kleber; M Topazian; J Gaspari; C E Riordan; T Kosten
Journal:  Am J Drug Alcohol Abuse       Date:  1987       Impact factor: 3.829

9.  Overlapping distributions of orexin/hypocretin- and dopamine-beta-hydroxylase immunoreactive fibers in rat brain regions mediating arousal, motivation, and stress.

Authors:  Brian A Baldo; Roger A Daniel; Craig W Berridge; Ann E Kelley
Journal:  J Comp Neurol       Date:  2003-09-15       Impact factor: 3.215

10.  Efficacy of clonidine and of methadone in the rapid detoxification of patients dependent on heroin.

Authors:  J Camí; S de Torres; L San; A Solé; D Guerra; B Ugena
Journal:  Clin Pharmacol Ther       Date:  1985-09       Impact factor: 6.875

View more
  28 in total

Review 1.  Drug Addiction: Hyperkatifeia/Negative Reinforcement as a Framework for Medications Development.

Authors:  George F Koob
Journal:  Pharmacol Rev       Date:  2021-01       Impact factor: 25.468

Review 2.  Antireward, compulsivity, and addiction: seminal contributions of Dr. Athina Markou to motivational dysregulation in addiction.

Authors:  George F Koob
Journal:  Psychopharmacology (Berl)       Date:  2017-01-03       Impact factor: 4.530

3.  Nicotinic receptor blockade decreases fos immunoreactivity within orexin/hypocretin-expressing neurons of nicotine-exposed rats.

Authors:  Steven J Simmons; Taylor A Gentile; Lili Mo; Fionya H Tran; Sisi Ma; John W Muschamp
Journal:  Behav Brain Res       Date:  2016-08-01       Impact factor: 3.332

4.  Sex Differences in Escalated Methamphetamine Self-Administration and Altered Gene Expression Associated With Incubation of Methamphetamine Seeking.

Authors:  Atul P Daiwile; Subramaniam Jayanthi; Bruce Ladenheim; Michael T McCoy; Christie Brannock; Jennifer Schroeder; Jean Lud Cadet
Journal:  Int J Neuropsychopharmacol       Date:  2019-11-01       Impact factor: 5.176

Review 5.  Modeling the development of drug addiction in male and female animals.

Authors:  Wendy J Lynch
Journal:  Pharmacol Biochem Behav       Date:  2017-06-15       Impact factor: 3.533

6.  Targeting the orexin system for prescription opioid use disorder: Orexin-1 receptor blockade prevents oxycodone taking and seeking in rats.

Authors:  Alessandra Matzeu; Rémi Martin-Fardon
Journal:  Neuropharmacology       Date:  2019-12-04       Impact factor: 5.250

7.  Introduction to the Special Issue: "Making orexin-based therapies for addiction a reality: What are the steps from here?"

Authors:  Morgan H James; Gary Aston-Jones
Journal:  Brain Res       Date:  2020-01-10       Impact factor: 3.252

8.  Compulsive-Like Sufentanil Vapor Self-Administration in Rats.

Authors:  Janaina C M Vendruscolo; Brendan J Tunstall; Stephanie A Carmack; Brooke E Schmeichel; Emily G Lowery-Gionta; Maury Cole; Olivier George; Sophia A Vandewater; Michael A Taffe; George F Koob; Leandro F Vendruscolo
Journal:  Neuropsychopharmacology       Date:  2017-08-16       Impact factor: 7.853

9.  Orexin-A/Hypocretin-1 Mediates Cocaine-Seeking Behavior in the Posterior Paraventricular Nucleus of the Thalamus via Orexin/Hypocretin Receptor-2.

Authors:  Alessandra Matzeu; Tony M Kerr; Friedbert Weiss; Rémi Martin-Fardon
Journal:  J Pharmacol Exp Ther       Date:  2016-08-18       Impact factor: 4.030

10.  Involvement of the orexin/hypocretin system in the pharmacological effects induced by Δ(9) -tetrahydrocannabinol.

Authors:  África Flores; Marina Julià-Hernández; Rafael Maldonado; Fernando Berrendero
Journal:  Br J Pharmacol       Date:  2016-03-03       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.